FDA Regeneron Sanofi Eczema Drug – CWEB.com

FDA Approves Regeneron and Sanofi’s Dupixent for Eczema: Regeneron Pharmaceuticals and Sanofi said they will charge $37,000 annually in the U.S. for their newly approved eczema drug, a price the companies said they reached after months of negotiations with pharmacy benefit managers.  The US Food and Drug Administration (FDA) today approved dupilumab  (Dupixent, Regeneron Pharmaceutics), a biologic for patients with moderate to severe atopic dermatitis – also called eczema – that spares them from the need to resort to higher-risk systemic immunosuppressants.